Our mission is to build shareholder value by rapidly developing and commercializing proven anti-cancer therapies in new high-impact orphan cancer indications where patients have failed modern biologic therapy.

Del Mar Pharma is developing new drug candidates targeting orphan cancer indications representing market opportunities in the US$100s of millions in North America and potentially billions of dollars worldwide. We aim to develop products that will have a high impact in patient care and a high return for our investors... more »

Our lead product candidate, VAL-083, benefits from an historical investment of more than US$50 million by the National Cancer Institute (NCI) in the United States. The drug is well-characterized and has been studied in more than 40 Phase I & Phase II NCI-sponsored human clinical trials.

Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia ("CML") and lung cancer... more »

• May 16: Corporate Update (Q1 2013)
• Apr 10: LifeSci Advisors April 10 2013 Update on DelMar
• Apr 10: DelMar Presents Encouraging Data from ongoing Trial with VAL-083
• Apr 1: DelMar to Present Clinical Trials Data for VAL-083 Brain Cancer Trial
• Mar 22: DelMar ROTH Capital Partners Growth Stock Conference Presentation
• Mar 13: LifeSci Advisors March 2013 Update on DelMar
• Mar 13: DelMar Named to Rocket Builders' 2013 "Ready to Rocket" List
• Mar 11: DelMar to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
• Mar 7: DelMar Announces Completion of $10.5M Oversubscribed Offering & Appointment of I.R. Consultant